In an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.
By Joseph Burns
Advertisement
Articles by By Joseph Burns
Advertisement
Latest Updated Articles
COME HOME Program Set to Save $33.5M Over 3 YearsAugust 25th 2014
Advertisement
Advertisement
Trending on OncLive
1
Pembrolizumab Biosimilar Meets Primary Phase 1 and Phase 3 End Points in NSCLC
2
T-DXd Plus Pertuzumab Sets New Treatment and Research Standards in HER2+ Breast Cancer
3
T-DXd Wins EU Approval for Previously Treated, HER2+ Metastatic Solid Tumors
4
The OncFive: Top Oncology Articles for the Week of 6/21
5